Platinum-sensitive Relapsed Ovarian Cancer
4 clinical trials · Condition
◉ Watch Platinum-sensitive Relapsed Ovarian Cancer
| Record | Firm | Date |
|---|---|---|
| Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer (NCT06446206) | The First Hospital of Jilin University | 2024-06-01 |
| Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient (NCT03705156) | Zai Lab (Shanghai) Co., Ltd. | 2017-06-08 |
| Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations (NCT02392676) | AstraZeneca | 2016-07-01 |
| Weekly Carboplatin and Taxotere in Platinum Sensitive Relapsed Ovarian or Tubal or Primary Peritoneal Cancers (NCT00247988) | University of Saskatchewan | 2003-10-01 |
Track Platinum-sensitive Relapsed Ovarian Cancer automatically
Every clearance here is in the API, with alerts when new ones post.